of Infectious Diseases, Infection Control, and Employee Health, The
University of Texas M.D. Anderson Cancer Center, Houston, Texas.
2 Department of Internal Medicine, Medical College of Georgia, Augusta University, GA, USA.
3 Department of Infectious Diseases Hospital do Servidor Publico estadul de Sao Paulo, Sao Paulo, Brazil.
4 Department of Infectious Diseases, Hospital Universitario Puerta de Hierro Segovia de Arana Majadahonda (Madrid).
5 Lianasmar Consulting.
6 Georgetown University, Washington, DC, USA.
7 Gilbert & Rose-Marie Chagoury School of Medicine, Lebanese American University, Beirut, Lebanon..
| This is an Open Access article distributed
under the terms of the Creative Commons Attribution License
(https://creativecommons.org/licenses/by-nc/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Candida bloodstream infection (BSI) remains one of the leading causes
of BSI in critically ill and immunosuppressed cancer patients. In light
of the changing epidemiology and rising resistant species, duration of
treatment and appropriate timing of stepdown therapy from intravenous
(IV) to oral antifungal agents are crucial for utmost disease control
and overall survival.
|Table 1. Patient Demographics and Characteristics by Countries (>5%).|
|Figure 1. Histogram showing the number of people (vertically) according to the type of Candida infection (horizontally).|
|Table 2. Survival Status for All Patients by Countries|
|Table 3. Sources of Infection for All Patients by Countries.|